Cover Image
市場調查報告書

憂鬱症治療及治療藥的全球市場:各國 (美國、加拿大、印度、中國、日本、英國) 市場、企業簡介、佔有率、趨勢、分析、規模、機會、分類和2015年∼2021年的預測

Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 345621
出版日期 內容資訊 英文 149 Pages
商品交期: 請詢問到貨日
價格
Back to Top
憂鬱症治療及治療藥的全球市場:各國 (美國、加拿大、印度、中國、日本、英國) 市場、企業簡介、佔有率、趨勢、分析、規模、機會、分類和2015年∼2021年的預測 Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年02月25日 內容資訊: 英文 149 Pages
簡介

抗憂鬱劑是對憂鬱症最為一般的治療方法。每年,全球開出50億件以上的處方箋。Eli Lilly、Pfizer、GlaxoSmithKline、Forest Laboratories等大型製藥公司加入。此外,設備市場成為最快速擴大的市場區隔。

本報告提供全球憂鬱症治療及治療藥市場相關調查、市場趨勢以及到2012年的收益預測與成長率、產業分析、競爭趨勢、各地區趨勢,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 市場概要 - 憂鬱症是全球性的大問題

  • 簡介
  • 憂鬱症以40∼60歲的年齡群最多
  • 憂鬱症的種類
  • 價值鏈分析
    • 藥物
    • 設備
  • 促進要素
  • 阻礙要素
  • 課題
  • 機會
  • 主要調查結果
  • 策略性建議

第3章 市場分類

  • 抗憂鬱劑
  • 抗憂鬱劑的消費
  • 選擇性血清素回收抑制劑(SSRIs)
  • 非定型抗憂鬱劑
  • 治療

第4章 性別罹患率

  • 男性
  • 女性

第5章 專利失效的學名藥市場擴大

第6章 競爭趨勢、策略、市場佔有率

  • 著重影響研究開發計畫的成本管理
  • 夥伴關係與收購
  • 關注專利失效和半法規市場的學名藥廠商
  • 市場佔有率分析

第7章 各地區分析

  • 在北美、歐洲、亞太地區中設備市場擴大
  • 北美最大的藥物市場
  • 歐洲憂鬱症是一大問題
  • 亞太地區學名藥市場大幅擴大

第8章 企業分析

  • Pfizer
  • GlaxoSmithKline
  • Forest Laboratories
  • Abbot Laboratories
  • Eli Lilly and Company
  • Merck Sharp &Dohme
  • Sanofi
  • Neuronetics
  • Teva pharmaceuticals Industries
  • Mayo Clinic
  • Sun Pharmaceuticals
  • Brainsway
  • Fisher Wallace
  • MagVentures
  • Lundbeck
  • BoehringerIngelheim GmbH
  • Roche Holding AG

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HPH-681114

Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment.

  • 1. Pfizer
  • 2. GlaxoSmithKline
  • 3. Forest Laboratories
  • 4. Abbot Laboratories
  • 5. Eli Lilly and Company
  • 6. Merck Sharp &Dohme
  • 7. Sanofi
  • 8. Teva Pharmaceuticals Industries
  • 9. Mayo Clinic
  • 10. Sun Pharmaceuticals
  • 11. Brainsway
  • 12. Fisher Wallace
  • 13. MagVentures
  • 14. Lundbeck
  • 15. BoehringerIngelheim GmbH
  • 16. Roche Holding AG
  • This Occams Research Report covers
  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR upto 2021
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data
  • 6. Deep profiles top competitive companies

Table of Contents

Chap 1. Executive Summary

  • 1.1. Depression therapy, device and drugs market
  • 1.2. Methodology For Market Estimation

Chap 2. Market Overview -Depression Is A Major Concern Worldwide

  • 2.1. Introduction
  • 2.2. Depression is most common in 40-60 years of age group
  • 2.3. Types of Depressions
    • 2.3.1. Seasonal Affective Disorder (SAD)
    • 2.3.2. Uni-polar or Major Depression
    • 2.3.3. Dysthymia or Dysthymia Disorder
    • 2.3.4. Postpartum Depression
    • 2.3.5. Atypical Depression
      • 2.3.5.1. Psychotic Depression
      • 2.3.5.2. Bipolar Disorder
  • 2.4. Value Chain Analysis
    • 2.4.1. For Drugs
      • 2.4.1.1. Manufacturers
      • 2.4.1.2. Distributors
      • 2.4.1.3. Retailers
      • 2.4.1.4. End-Users
    • 2.4.2. For Devices
      • 2.4.2.1. Manufacturers
      • 2.4.2.2. Distributors
      • 2.4.2.3. End-Users
  • 2.5. Drivers
    • 2.5.1. Growing acceptance of Depression in the developing nations
    • 2.5.2. Increase in sales of antidepressants due to unhealthy life styles
  • 2.6. Restraints
    • 2.6.1. High price of Psycho therapy is a major restraint
    • 2.6.2. Patents expiry is a major issue
    • 2.6.3. Regulatory Compliance is important for the market to grow
  • 2.7. Challenges
    • 2.7.1. Generic Vs Branded - leads to price reduction
  • 2.8. Opportunities
    • 2.8.1. Significant Unmet Clinical needs has tremendous market potential
    • 2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
  • 2.9. Key Findings
    • 2.9.1. Negative Growth Rate in Antidepressants market
    • 2.9.2. Rising acceptance for depression treatment in Asia Pacific
    • 2.9.3. Market is shifting from branded to generic drugs
  • 2.10. Strategic Recommendations
    • 2.10.1. Market needs new anti depressant drugs

Chap 3. Market Segmentation

  • 3.1. Antidepressants
  • 3.2. Consumption of Antidepressants
    • 3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
  • 3.3. Selective serotonin reuptake inhibitors (SSRIs)
    • 3.3.1. Prozac (Fluoxetine)
    • 3.3.2. Paroxetine (Paxil)
    • 3.3.3. SERTRALINE (Zoloft)
    • 3.3.4. Escitalopram oxalate (Lexapro)
    • 3.3.5. Citalopram (Celexa)
    • 3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
    • 3.3.7. Duloxetine (Cymbalta)
    • 3.3.8. Effexor
    • 3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
  • 3.4. Atypical antidepressants
    • 3.4.1. Trazodone
    • 3.4.2. Tricyclic antidepressants (TCA)
    • 3.4.3. Tofranil (Imipramine)
    • 3.4.4. Monoamine oxidase inhibitors (MAOIs)
    • 3.4.4.1. Tranylcypromine (Parnate)
    • 3.4.5. Phenelzine (Nardil)
    • 3.4.6. Other medications
  • 3.5. Therapies
    • 3.5.1. Cognitive Behavior Therapy (CBT)
    • 3.5.2. Electroconvulsive Therapy (ECT)
    • 3.5.3. Rational emotive behavior therapy (REBT)
    • 3.5.4. Device enabled therapies
      • 3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy
      • 3.5.4.2. Deep Brain Stimulation
      • 3.5.4.3. Vagus Nerve Stimulator
      • 3.5.4.4. Virtual Reality (VR)
      • 3.5.4.5. Smart phone applications
    • 3.5.5. Other Therapies
      • 3.5.5.1. Ketamine therapy
    • 3.5.6. Special Conditions
      • 3.5.6.1. Antidepressants discontinuation syndrome (ADS)
      • 3.5.6.2. Treatment-resistant depression
      • 3.5.6.3. Rehabilitation centre for depression
      • 3.5.6.4. Rehabilitation programs through VR technology

Chap 4. Depression Prevalence by Gender

  • 4.1. Depression in Men
  • 4.2. Depression in Women
    • 4.2.1. Depression in Elderly is a common phenomenon

Chap 5. Resurgent Generic Drugs market due to patent expiry

Chap 6. Competitive Trends, Strategies & Market Share

  • 6.1. Key Focus on Cost Control Impacting R&D Initiatives
  • 6.2. Partnerships and acquisitions
  • 6.3. Generic drug manufacturers focusing on patent expiration and semi regulated markets
  • 6.4. Market Share Analysis

Chap 7. Geographical analysis

  • 7.1. Devices market is growing in North America, Europe and Asia Pacific
  • 7.2. North America is the highest drug market for depression
    • 7.2.1. US has the largest patient pool for depression drugs & devices
    • 7.2.2. US market is driven by strict regulations
    • 7.2.3. Mental illness is a major disease in Canada
  • 7.3. Depression is a major concern in Europe
    • 7.3.1. almost 16.7 million people suffer from depression in the UK
    • 7.3.2. Regulations in the United Kingdom
    • 7.3.3. France has the highest rate of depression amongst developed nations
    • 7.3.4. Germany has prevalence rate of 4.5-5% for depression
    • 7.3.5. Spain has strict regulations for depression drugs
  • 7.4. Asia Pacific has a strongly emerging generic drugs market
    • 7.4.1. Approx 60% of the population in China is undiagnosed for depression
    • 7.4.2. India has over 10 million people suffering from depression
    • 7.4.3. Financial burden of depression in Japan amounts to nearly $15 billion
    • 7.4.4. Depression is a common occurring health issue in the age group 12-25 years in Australia

Chap 8. Corporate profiling

  • 8.1. Pfizer
    • 8.1.1. Overview
    • 8.1.2. Strategic Analysis
    • 8.1.3. SCOT Analysis
  • 8.2. GlaxoSmithKline
    • 8.2.1. Overview
    • 8.2.2. SCOT Analysis
  • 8.3. Forest Laboratories
    • 8.3.1. Overview
    • 8.3.2. SCOT Analysis
  • 8.4. Abbot Laboratories
    • 8.4.1. Overview
    • 8.4.2. SCOT Analysis
  • 8.5. Eli Lilly and Company
    • 8.5.1. Overview
    • 8.5.2. SCOT Analysis
  • 8.6. Merck Sharp &Dohme
    • 8.6.1. Overview
    • 8.6.2. SCOT Analysis
  • 8.7. Sanofi
    • 8.7.1. Overview
    • 8.7.2. SCOT Analysis
  • 8.8. Neuronetics
    • 8.8.1. Overview
    • 8.8.2. SCOT Analysis
  • 8.9. Teva pharmaceuticals Industries
    • 8.9.1. Overview
    • 8.9.2. SCOT Analysis
  • 8.10. Mayo Clinic
    • 8.10.1. Overview
    • 8.10.2. Mayo Clinic product portfolio in depression therapy
    • 8.10.3. SCOT Analysis
  • 8.11. Sun Pharmaceuticals
    • 8.11.1. Overview
    • 8.11.2. SCOT Analysis
  • 8.12. Brainsway
    • 8.12.1. Overview
    • 8.12.2. SCOT Analysis
  • 8.13. Fisher Wallace
    • 8.13.1. Overview
    • 8.13.2. SCOT Analysis
  • 8.14. MagVentures
    • 8.14.1. Overview
  • 8.15. Lundbeck
    • 8.15.1. Overview
    • 8.15.2. Strategic moves
    • 8.15.3. SCOT Analysis
  • 8.16. BoehringerIngelheim GmbH
    • 8.16.1. Overview
    • 8.16.2. SCOT Analysis
  • 8.17. Roche Holding AG
    • 8.17.1. Overview
    • 8.17.2. Strategic Moves
    • 8.17.3. SCOT Analysis

Table List

  • TABLE 1 Global Depression Drugs and Devices Market 2013- 2021 (In $million)
  • TABLE 2 Timeline of the branded drug expiration/Launch in the U.S.
  • TABLE 3 R& D spending by pharmaceutical giants in 2013
  • TABLE 4 Global antidepressants drug market, 2013-2021 (in $million)
  • TABLE 5 Price of Flouoxetine in different drug store in 2012
  • TABLE 6 Price of Paroxetine (Paxil), North America
  • TABLE 7 Global Sertaline drug market, 2013-2021, (in $million)
  • TABLE 8 Price and drug attribute of Lexapro
  • TABLE 9 Price and Package details of Cymbalta
  • TABLE 10 Table: U.S. Price of Effexor of different strength
  • TABLE 11 Price of Bupropion (Wellbutrin)
  • TABLE 12 Price of Trazodone of different strength
  • TABLE 13 Price of Tofranil of different strength
  • TABLE 14 Price of Tranylcypromine (Parnate)
  • TABLE 15 Global virtual reality in healthcare market, 2013-2021 (in $million)
  • TABLE 16 Difference between male and female depression behavior
  • TABLE 17 Global depression drugs and device market, 2013-2021, ($million)
  • TABLE 18 North America depression drugs and device market, 2013-2021, (in $million)
  • TABLE 19 France has the highest prevalence rate in EU in (2014)
  • TABLE 20 European depression therapy and device market, 2013-2021, ($million)
  • TABLE 21 Asia Pacific depression drugs and device market, 2013-2021, (in $million)
  • TABLE 22 Pfizer product portfolio in depression therapy
  • TABLE 23 GlaxoSmithKline product portfolio in depression therapy:
  • TABLE 24 Forest Laboratories product portfolio in depression therapy
  • TABLE 25 Abbot Laboratories' product portfolio in depression therapy
  • TABLE 26 Eli Lilly and Company product portfolio in depression therapy
  • TABLE 27 Sanofi product portfolio in depression therapy
  • TABLE 28 Neuronetics products portfolio in depression therapy
  • TABLE 29 Teva pharmaceuticals Industries product portfolio in depression therapy
  • TABLE 30 MagVentures product portfolio in depression therapy
  • TABLE 31 Lundbeck product portfolio in depression therapy
  • TABLE 32 Roche AG product portfolio in depression therapy

Figures List

  • FIGURE 1 DEPRESSION PREVALANCE-FACT SHEET
  • FIGURE 2 Worldwide Prevalence of depression by age and gender in 2013
  • FIGURE 3 High rate of depression in American Indian and Alaska Native -12 month prevalence of major depressive episode among U.S. adults (2012)
  • FIGURE 4 Lifetime prevalence RATE OF DEPRESSION IN US ADULTS, 2012
  • FIGURE 5 Dysthymia PATIENTS BY TREATMENT
  • FIGURE 6 Value Chain of Antidepressant drugs
  • FIGURE 7 Value Chain Analysis for Device Market
  • FIGURE 8 CAUSES OF DEPRESSION-(FACTORS BY PERCENTAGE, 2013)
  • FIGURE 9 Branded Antidepressant drug sales in $million (2003-2012)
  • FIGURE 10 Global Antidepressants drug market in $million (2013-2021)
  • FIGURE 11 Savings through generic drug usage in the United States in $billion (2004-2013)
  • FIGURE 12 Side effects of antidepressants
  • FIGURE 13 Global Flouoxetine market, 2013-2017, (in $million)
  • FIGURE 14 Global Escilatopram drug market, 2013-2021 (in $million)
  • FIGURE 15 Price of Citalopram (Celexa)
  • FIGURE 16 Global Duloexitine market, 2013-2021, (in $million)
  • FIGURE 17 Global Venlafexine drug market, 2013-2021, ($million)
  • FIGURE 18 Global Transcranial Magnetic Stimulation Market, 2013-2021(in $million)
  • FIGURE 19 Global Deep Brain Stimulation Market, 2013-2021, (in $million)
  • FIGURE 20 Global Vagus Nerve Stimulation Market, 2013-2021(in $million)
  • FIGURE 21 coMPARISON OF MALE AND FEMALE DEPRESSION
  • FIGURE 22 Market Share of major antidepressants in 2021 (%)
  • FIGURE 23 Market Share of antidepressants drug manufacturers (percentage of sales), 2014
  • FIGURE 24 GEOGRAPHICAL DISTRIBUTION OF prevalence rate of depression, 2013
  • FIGURE 25 Devices Market (percentage sales) to be the largest in 2021
  • FIGURE 26 The U.S. depression therapy market, 2013-2021 ($million)
  • FIGURE 27 Canada depression therapy market, 2013-2021, ($million)
  • FIGURE 28 European depression treatment device and therapy market, 2013-2021 ($million)
  • FIGURE 29 Devices market will double (percentage sales) in 2021 from 2013
  • FIGURE 30 Total cost of mental illness in England (in $)
  • FIGURE 31 United Kingdom depression therapy market, 2013-2021 ($million)
  • FIGURE 32 France depression therapy market, 2013-2021 ($million)
  • FIGURE 33 Germany depression therapy market, 2013-2021 ($million)
  • FIGURE 34 Spain depression therapy market, 2013-2021 ($million)
  • FIGURE 35 China depression therapy market, 2013-2021, ($million)
  • FIGURE 36 India depression therapy market, 2013-2021, ($million)
  • FIGURE 37 Japan depression therapy market, 2013-2021, ($million)
  • FIGURE 38 Australia depression Therapy market, 2013-2021, ($million)
  • FIGURE 39 Sun Pharmaceuticals products portfolio in depression therapy
  • FIGURE 40 Brainsway product portfolio in depression therapy
  • FIGURE 41 Fisher Wallace product portfolio in depression therapy
Back to Top